DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Phase 1

Active, not recruiting

Conditions: Healthy Volunteers
Hepatic Steatosis

Interventions: Drug: NNC0581-0001
Drug: Placebo (NNC0581-0001)

First Posted Date: 2022-10-31

Last Posted Date: 2025-04-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT05599945

Locations: 🇬🇧
Parexel Research Unit, Harrow, Middlesex, United Kingdom
🇬🇧
Parexel CPRU, Level 7, Harrow, Middlesex, United Kingdom

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: Semaglutide
Drug: Orlistat
Drug: Phentermine/Topiramate
Drug: Naltrexone/Bupropion
Drug: Liraglutide

First Posted Date: 2022-10-13

Last Posted Date: 2025-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 500

Registration Number: NCT05579249

Locations: 🇺🇸
Nutrition Research Centre, Loma Linda, California, United States

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Placebo semaglutide
Drug: Placebo cagrilintide

First Posted Date: 2022-10-05

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3400

Registration Number: NCT05567796

Locations: 🇦🇺
Momentum Clinical Research, Taringa, Queensland, Australia
🇧🇪
Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden, Belgium
🇧🇪
CHR Mons-Hainaut - Site Warquignies, Boussu, Belgium

and more 215 locations

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo semaglutide

First Posted Date: 2022-10-03

Last Posted Date: 2025-04-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 307

Registration Number: NCT05564117

Locations: 🇵🇱
ETG Siedlce, Siedlce, Masovian, Poland
🇵🇱
ETG Warszawa, Warsaw, Masovian, Poland
🇩🇪
MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin, Münster, Germany

and more 19 locations

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Cagrilintide

First Posted Date: 2022-10-03

Last Posted Date: 2025-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT05564104

Locations: 🇩🇪
APEX Research, München, Germany
🇸🇰
Summit Clinical Research s.r.o., Malacky, Slovakia

A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2022-09-15

Last Posted Date: 2024-06-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3000

Registration Number: NCT05542420

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2022-09-09

Last Posted Date: 2025-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 104

Registration Number: NCT05533632

Locations: 🇨🇱
Hospital San Juan de Dios_Santiago, Región Metropolitana, Santiago, Región Metropolitana, Chile
🇨🇱
Hospital Padre Hurtado, Santiago, Región Metropolitana, Chile
🇨🇱
Servicios Médicos Godoy Limitada, Santiago, Región Metropolitana, Chile

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Phase 1

Completed

Conditions: Healthy Volunteers
Type 2 Diabetes

Interventions: Drug: NNC0113-6856
Drug: Placebo

First Posted Date: 2022-08-30

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT05521256

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: Insuline glargine U100 (titrated)
Drug: Semaglutide
Drug: Insuline glargine U100 (reduced)

First Posted Date: 2022-08-24

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 568

Registration Number: NCT05514535

Locations: 🇬🇷
EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes, Thessaloniki, Greece
🇬🇷
"Thermi" Private Hosital, Thessaloniki, Greece
🇮🇹
Ospedale Santa Maria Goretti - UOD Diabetologia, Latina, LT, Italy

and more 103 locations

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Conditions: Obesity
Overweight
Pregnancy

Interventions: Other: No Intervention

First Posted Date: 2022-08-17

Last Posted Date: 2024-12-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1139

Registration Number: NCT05503927

Locations: 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy